Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Monday, May 27, 2024 for the Memorial Day holiday. Have a healthy, happy holiday.


COVID-19, flu, and RSV combination testing

Know more, sooner, with COVID-19 and respiratory molecular combination testing

SARS-CoV-2 (COVID-19), influenza, RSV, and other respiratory viruses can present with similar symptoms such as fever, cough, and shortness of breath. For at-risk groups1-3 or patients with a more acute illness, an expedited diagnosis is crucial, so treatment can be initiated while it’s most effective.1-3 That’s why it’s important to test for each of these illnesses at the same time.

Testing that supports a faster diagnosis

When a patient presents in-office with respiratory illness symptoms, send the specimen directly to Quest for the convenience of combination testing. Our SARS-CoV-2 (COVID-19) and respiratory molecular combination tests use a single specimen to test for common respiratory viruses, providing timely results to help you develop an appropriate care plan.

Why choose SARS-CoV-2 (COVID-19) and respiratory molecular combination tests for your patients

Combination testing options from Quest Diagnostics

Other respiratory testing options

Panel components may be ordered separately.

PSC testing availability

SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT combination test is now available for collection at Quest Patient Service Centers (PSCs) for patients with mild symptoms.

COVID-19 testing statements

  • The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
  • All tests have been authorized by FDA under EUAs for use by authorized laboratories;
  • The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
  • The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses, pathogens; and,
  • All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.


  1. CDC. Factors that affect your risk of getting very sick from COVID-19. Updated October 19, 2022. Accessed October 25, 2022.
  2. CDC. Flu treatment. Updated October 11, 2022. Accessed October 25, 2022.
  3. CDC. RSV. Updated December 18, 2020. Accessed October 20, 2022.
  4. Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA’s diagnostics committee. Clin Infect Dis. 2020;71(10):2744-2751. doi:10.1093/cid/ciaa508


For more information on our combination testing solutions, or to set up a Quest account, connect with a Quest representative.

Contact us